The abstract is read at the publisher; the summary is JClub's.
In the Million Veteran Program, high P-CARE germline genomic risk is linked to higher hazards of treatment (HR 3.32) and metastasis (HR 3.32) than low risk.
- Why it matters: PSA alone may miss men with elevated inherited risk, so adding germline genomic information could improve early detection and risk stratification for prostate cancer.
- What they did: P-CARE combines a 601-variant polygenic hazard score, family history, and genetic ancestry; associations with long-term outcomes and clinically significant prostate cancer on biopsy were tested in MVP and externally validated in PCPT.
- The result: For PSA 1–3 ng/mL at ages 40–49, 15-year treatment/metastasis probabilities rose from 2.6% to 10.2% across P-CARE risk groups, and high P-CARE predicted csPCa on biopsy (OR 2.96), consistent in PCPT.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.